A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)

Trial Profile

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms SURVEYOR-II
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Oct 2017 Results of an integrated analysis from ENDURANCE-1, ENDURANCE-2, ENDURANCE-3, ENDURANCE-4, EXPEDITION-1, EXPEDITION-4, SURVEYOR-II, and MAGELLAN-1 studies, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 19 Sep 2017 Results (n=131) assessing safety and efficacy of ABT-493 and ABT-530 coadministered with and without ribavirin in adults with chronic hepatitis C virus (HCV) genotype 2,3, 4, 5 or 6 infection, were published in the Hepatology.
    • 28 Jul 2017 According to an Enanta Pharmaceuticals media release, the European Commission (EC) granted AbbVie marketing authorization for MAVIRET (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). The approval of MAVIRET is supported by data from eight registrational studies in AbbVie's clinical development program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top